Cabergoline for nonfunctioning pituitary tumors
Treatments studied
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This trial tests if cabergoline, a medicine, can help shrink nonfunctioning pituitary adenomas (benign tumors on the pituitary gland that don't produce excess hormones). It may be an option for people who have not had prior radiation or surgery, and whose tumors are at least 0.5 cm in size.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a pituitary tumor (nonfunctioning) that is 0.5 cm or larger in size.
- You have not had radiation or surgery on the pituitary before.
- You are not allergic to cabergoline or ergotamine.
- You do not have serious symptoms from the tumor, like vision problems or severe headaches.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of PET/MRI scan that uses a special tracer (18F-FET) to better find small pituitary tumors that didn't show up on a standard MRI. The goal is to help guide surgery to remove the tumor.
This study looks at whether blood and tissue markers, along with imaging features, can predict how aggressive a pituitary neuroendocrine tumor is and how it may affect long-term health. It aims to improve treatment decisions by better understanding these tumors.
This trial tests hydrocortisone as hormone replacement therapy after surgery for large pituitary tumors. It aims to help patients maintain healthy cortisol levels during recovery.
This trial tests a higher dose of the drug cabergoline to see if it works better for small prolactin-secreting tumors (microprolactinomas) in premenopausal women who have not been treated before. It aims to find a safe and effective way to lower high prolactin levels and shrink the tumor.
This study looks at metabolic health (like blood sugar and cholesterol) in people with prolactinomas who are being treated with the drug cabergoline. It aims to understand how lowering prolactin affects the body's metabolism and may help guide better care for patients with this condition.
This trial tests if cabergoline can help reduce high prolactin levels caused by antipsychotic medications in people with schizophrenia. It may be an option if you have symptoms like breast tenderness, milk production, or sexual side effects.
Hear when a new Pituitary Adenoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.